Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-02-01

FDA Approved: TRI-ESTARYLLA — Supplemental Application (Xiromed, LLC.)

View source ↗

Summary

FDA approved a supplemental application for Tri-Estarylla (norgestimate and ethinyl estradiol) from Xiromed, LLC., supporting an additional or updated label for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRI-ESTARYLLA (NORGESTIMATE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for TRI-ESTARYLLA (NORGESTIMATE AND ETHINYL ESTRADIOL)